The agency set aside concerns about UroGen’s approval trial to greenlight mitomycin intravesical solution for recurrent non-muscle invasive bladder cancer.

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...